Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
AKRX's Cash to Debt is ranked lower than
53% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. AKRX: 0.07 )
AKRX' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.07

Equity to Asset 0.20
AKRX's Equity to Asset is ranked lower than
51% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. AKRX: 0.20 )
AKRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.86
Current: 0.2

0.18
0.86
F-Score: 4
Z-Score: 2.88
M-Score: -0.92
WACC vs ROIC
5.47%
6.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 16.31
AKRX's Operating margin (%) is ranked higher than
86% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. AKRX: 16.31 )
AKRX' s 10-Year Operating margin (%) Range
Min: -50.73   Max: 27.76
Current: 16.31

-50.73
27.76
Net-margin (%) 5.96
AKRX's Net-margin (%) is ranked higher than
72% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. AKRX: 5.96 )
AKRX' s 10-Year Net-margin (%) Range
Min: -36.46   Max: 31.41
Current: 5.96

-36.46
31.41
ROE (%) 11.51
AKRX's ROE (%) is ranked higher than
84% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. AKRX: 11.51 )
AKRX' s 10-Year ROE (%) Range
Min: -108.38   Max: 35.12
Current: 11.51

-108.38
35.12
ROA (%) 2.99
AKRX's ROA (%) is ranked higher than
72% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. AKRX: 2.99 )
AKRX' s 10-Year ROA (%) Range
Min: -33.5   Max: 24.27
Current: 2.99

-33.5
24.27
ROC (Joel Greenblatt) (%) 33.64
AKRX's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. AKRX: 33.64 )
AKRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -41.62   Max: 56.75
Current: 33.64

-41.62
56.75
Revenue Growth (3Y)(%) 54.00
AKRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. AKRX: 54.00 )
AKRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37   Max: 54
Current: 54

-37
54
EBITDA Growth (3Y)(%) 37.00
AKRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. AKRX: 37.00 )
AKRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.1   Max: 171.4
Current: 37

-67.1
171.4
EPS Growth (3Y)(%) -2.50
AKRX's EPS Growth (3Y)(%) is ranked higher than
69% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. AKRX: -2.50 )
AKRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4   Max: 93.1
Current: -2.5

-50.4
93.1
» AKRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AKRX Guru Trades in Q1 2014

Pioneer Investments 297,868 sh (New)
Mario Gabelli 15,900 sh (New)
Jim Simons 29,100 sh (New)
Joel Greenblatt 68,119 sh (+283.01%)
Columbia Wanger 7,263,695 sh (unchged)
Steven Cohen Sold Out
Columbia Wanger 7,215,700 sh (-0.66%)
» More
Q2 2014

AKRX Guru Trades in Q2 2014

Murray Stahl 26,464 sh (New)
Columbia Wanger 8,123,700 sh (+12.58%)
Jim Simons Sold Out
Pioneer Investments 254,698 sh (-14.49%)
Mario Gabelli 9,950 sh (-37.42%)
Joel Greenblatt 39,285 sh (-42.33%)
» More
Q3 2014

AKRX Guru Trades in Q3 2014

Steven Cohen 49,100 sh (New)
Paul Tudor Jones 14,400 sh (New)
Pioneer Investments 213,151 sh (unchged)
Mario Gabelli 9,300 sh (-6.53%)
Murray Stahl 23,011 sh (-13.05%)
Columbia Wanger 6,846,275 sh (-15.72%)
Joel Greenblatt 24,479 sh (-37.69%)
» More
Q4 2014

AKRX Guru Trades in Q4 2014

Steven Cohen 121,600 sh (+147.66%)
Joel Greenblatt 26,536 sh (+8.40%)
Pioneer Investments Sold Out
Paul Tudor Jones 14,300 sh (-0.69%)
Murray Stahl 22,606 sh (-1.76%)
Columbia Wanger 6,524,486 sh (-4.70%)
Mario Gabelli 7,500 sh (-19.35%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 146.10
AKRX's P/E(ttm) is ranked higher than
65% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. AKRX: 146.10 )
AKRX' s 10-Year P/E(ttm) Range
Min: 13.23   Max: 244.78
Current: 146.1

13.23
244.78
Forward P/E 20.04
AKRX's Forward P/E is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. AKRX: 20.04 )
N/A
PE(NRI) 142.60
AKRX's PE(NRI) is ranked higher than
67% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. AKRX: 142.60 )
AKRX' s 10-Year PE(NRI) Range
Min: 13.17   Max: 234.47
Current: 142.6

13.17
234.47
P/B 13.40
AKRX's P/B is ranked lower than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. AKRX: 13.40 )
AKRX' s 10-Year P/B Range
Min: 1.42   Max: 41.45
Current: 13.4

1.42
41.45
P/S 9.50
AKRX's P/S is ranked lower than
51% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. AKRX: 9.50 )
AKRX' s 10-Year P/S Range
Min: 0.76   Max: 12.87
Current: 9.5

0.76
12.87
POCF 193.92
AKRX's POCF is ranked higher than
68% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. AKRX: 193.92 )
AKRX' s 10-Year POCF Range
Min: 23.75   Max: 215.24
Current: 193.92

23.75
215.24
EV-to-EBIT 67.96
AKRX's EV-to-EBIT is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. AKRX: 67.96 )
AKRX' s 10-Year EV-to-EBIT Range
Min: -430.4   Max: 97.1
Current: 67.96

-430.4
97.1
Shiller P/E 202.80
AKRX's Shiller P/E is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.82 vs. AKRX: 202.80 )
AKRX' s 10-Year Shiller P/E Range
Min: 110.53   Max: 728
Current: 202.8

110.53
728
Current Ratio 3.68
AKRX's Current Ratio is ranked higher than
81% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AKRX: 3.68 )
AKRX' s 10-Year Current Ratio Range
Min: 0.3   Max: 5.51
Current: 3.68

0.3
5.51
Quick Ratio 2.71
AKRX's Quick Ratio is ranked higher than
79% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AKRX: 2.71 )
AKRX' s 10-Year Quick Ratio Range
Min: 0.06   Max: 4.26
Current: 2.71

0.06
4.26
Days Inventory 121.31
AKRX's Days Inventory is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. AKRX: 121.31 )
AKRX' s 10-Year Days Inventory Range
Min: 42.24   Max: 188.37
Current: 121.31

42.24
188.37
Days Sales Outstanding 135.84
AKRX's Days Sales Outstanding is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. AKRX: 135.84 )
AKRX' s 10-Year Days Sales Outstanding Range
Min: 10.09   Max: 135.84
Current: 135.84

10.09
135.84

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 14.69
AKRX's Price/DCF (Projected) is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. AKRX: 14.69 )
AKRX' s 10-Year Price/DCF (Projected) Range
Min: 8.35   Max: 50.58
Current: 14.69

8.35
50.58
Price/Median PS Value 1.65
AKRX's Price/Median PS Value is ranked higher than
66% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. AKRX: 1.65 )
AKRX' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.01
Current: 1.65

0.08
2.01
Earnings Yield (Greenblatt) 1.50
AKRX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. AKRX: 1.50 )
AKRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 5.3
Current: 1.5

1
5.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FDA.Germany,
Akorn Inc is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. In addition, it has markets and distributes vaccines purchased from outside sources. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. It also operates a Research and Development center in Vernon Hills, Illinois and a distribution warehouse in Gurnee, Illinois. Its three operating segments are: ophthalmic; hospital drugs & injectables; contract services. Ophthalmic Segment: It markets a full line of diagnostic and therapeutic ophthalmic pharmaceutical products. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others. Therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers, include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers. Hospital Drugs & Injectables Segment - it markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia, and other selected pharmaceutical products. These products are predominately sold to hospitals through the wholesale distribution channel. The Companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company targets products with limited competition due to difficulty in manufacturing and/or the products market size. Contract Services Segment: It manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The Company is competitors for hospital drugs & injectables segment include both generic and name brand companies such as Hospira, Inc., Teva Pharmaceutical Industries, Pfizer, Sagent Pharmaceuticals, Novartis, Fresenius-Kabi, Daiichi Sankyo, and Hikma. For ophthalmic segment its competitors include, Allergan Pharmaceuticals, Inc., Novartis, Valeant Pharmaceuticals International, Inc., Apotex and Sun Pharmaceuticals, among others.
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 22 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 
Akorn Inc. Reports Operating Results (10-Q) Nov 09 2009 
Weekly CFO Buy Highlights: Gigatronics Inc., Akorn Inc., MainSource Financial Group Inc, U.S. Auto P Sep 06 2009 
Akorn Inc. Reports Operating Results (10-Q) Aug 17 2009 

More From Other Websites
Which 4 Big Drugmakers Have Rising Estimates? Mar 27 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Akorn,... Mar 25 2015
AKORN INC Financials Mar 24 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Akorn,... Mar 20 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of AKORN, INC. of PENDENCY OF CLASS... Mar 20 2015
Akorn Launches Phenylephrine HCl Ophthalmic Solution Mar 20 2015
AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog Mar 19 2015
Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capital’s Winning Bets... Mar 19 2015
Strength Seen in Parnell (PARN): Stock Rises 9.1% - Tale of the Tape Mar 19 2015
Investors Relieved? Akorn Stock Retakes 50-Day Line Mar 18 2015
Teva Sells Four Oncology Development Assets to Ignyta - Analyst Blog Mar 18 2015
AstraZeneca Presents Encouraging Heart Drug Brilinta Data - Analyst Blog Mar 18 2015
Akorn (AKRX) Stock Higher Today After Filing 2014 Annual Report Mar 18 2015
Why Akorn (AKRX) Isn't Done Growing Earnings Yet - Tale of the Tape Mar 18 2015
Akorn Leads 5 Drug Stocks Moving After Hours On News Mar 17 2015
Actavis' Depression Drug Gains FDA Approval for New Dose - Analyst Blog Mar 17 2015
AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on... Mar 17 2015
Akorn Files Annual Report on Form 10-K for Year Ended December 31, 2014; Restates Second and Third... Mar 17 2015
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Mar 16 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Mar 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK